| Popis: |
Introduction: The induction and inhibition of cytochrome P450 are associated with multiple pharmacological interactions, which can lead to loss of efficacy or increase the risk of adverse drug reactions. Objective: To determine the prescription patterns of cytochrome P450-inducing and -inhibiting drugs and their contraindicated and major pharmacological interactions in a group of patients from Colombia. Materials and methods: This cross-sectional study included patients who received drugs that induce or inhibit metabolism and examined their contraindicated and major pharmacological interactions. The patients were identified from a population database and the Micromedex® tool. Results: A total of 63,433 patients were analyzed, with a median age of 61 years, and 63.1% were women. Antiepileptics (35.9%) and antifungals (27.6%) were the most commonly used inducers and inhibitors. A total of 30.1% of patients had potential contraindicated or greater interactions. The following factors were associated with a higher probability of presenting a potential pharmacological interaction: being male (OR: 1.14; 95% CI: 1.10-1.19), being between 18-39 years (OR: 1.77; 95% CI 1.67-1.89) or between 40-64 years (OR: 1.64; 95% CI: 1.56-1.72), having neurological diseases (OR: 1.28; 95% CI: 1.21-1.35), having psychiatric diseases (OR: 3.84; 95% CI: 3.58-4.13), having rheumatologic diseases (OR: 1.32; 95% CI: 1.23-1.41), receiving comedications with statins (OR: 1.14; 95% CI: 1.08-1, 19), receiving comedications with analgesics (OR: 1.33; 95% CI: 1.27-1.38), receiving comedications with antiparasitics (OR: 2.88; 95% CI: 2.66-3.11), and an increase in the number of medications (OR: 1.24; 95% CI: 1.23-1.25). Conclusions:Among the users of cytochrome P450 inhibitors and inducers, potential contraindications and greater interactions are very common, especially in men under 65 years of age with comorbidities and polypharmacy. |
